Published by Michele Maatouk on 4th December 2024
(Sharecast News) - Eli Lilly said on Wednesday that a clinical trial had shown that patients taking its weight-loss drug Zepbound (tirzepatide) lost 47% more weight than those taking Novo Nordisk's Wegovy (semaglutide).
URL: http://www.digitallook.com/dl/news/story/34732618/...